广济药业拟向控股股东定增募资6亿元以优化资本结构

Group 1 - The company Guangji Pharmaceutical (000952.SZ) plans to raise funds through a private placement to its controlling shareholder, Changjiang Industrial Investment Group, by issuing up to 94,936,708 shares at a price of 6.32 yuan per share, with total fundraising not exceeding 600 million yuan [1] - The funds raised will primarily be used to repay loans and supplement working capital, aiming to optimize the capital structure and reduce the debt-to-asset ratio, which is currently at 62.67% as of September 30, 2025 [1] - The company has been facing continuous losses from 2023 to 2025, with increasing loss amounts due to prolonged low sales prices of its main products, including Vitamin B2 and B6, amid intensified market competition [1] Group 2 - Market research institutions predict that Vitamin B2 may enter a period of moderate growth starting in 2026, which could impact the company's future performance positively [1] - The company's ability to withstand the cyclical downturn with the support of its controlling shareholder remains to be observed [1]